Cell-based pcsk9 screening assay
AssigneeBoard of Regents, The University of Texas System
InventorsJay D. Horton, Markey C. McNutt
Life of this patent
Estimating the term…
Abstract
The present invention includes a PCSK9 activity inhibition assay system, kits, compositions and methods. The present invention includes a cell having a first vector capable of expressing a catalytic fragment of PCSK9, a second vector capable of expressing a prodomain of PCSK9 and a V5 protein with a detectable label. The V5 protein forms a fusion protein with the prodomain of PCSK9 and wherein cleavage of the prodomain by the catalytic fragment of PCSK9 releases a detectable signal.
Claims20
A PCSK9 activity inhibition assay system comprising:
- a cell comprising:
- a first vector capable of expressing a catalytic fragment of PCSK9;
- a second vector capable of expressing a prodomain of PCSK9;
- and
- a V5 protein comprising a detectable label, wherein the V5 protein forms a fusion protein with the prodomain of PCSK9 and wherein cleavage of the prodomain by the catalytic fragment of PCSK9 releases a detectable signal.
A cell-based method of screening molecules for inhibition of PCSK9 catalytic activity comprising the steps of:
- providing one or more cells comprising a first vector capable of expressing a catalytic fragment of PCSK9, a second vector capable of expressing a prodomain of PCSK9 and a source of V5 protein having a detectable label to form a V5 prodomain chimera, wherein the V5 protein is linked to the C-terminus of the prodomain;
- contacting the one or more cells with a sample suspected of comprising a PCSK9 catalytic activity inhibitor;
- and
- detecting the presence of the detectable label, wherein the catalytic fragment of PCSK9 cleaves the detectable labelto provide a cell-based assay that can be used to screen molecules for inhibition of PCSK9 catalytic activity.
A PCSK9 inhibition assay kit comprising:
- a first vector capable of expressing a catalytically active fragment of PCSK9;
- a second vector capable of expressing a prodomain of PCSK9;
- and
- a detectable label to form a detectable label prodomain fusion protein, wherein the catalytic fragment of PCSK9 cleaves the detectable label to provides a cell-based assay to screen molecules for inhibition of PCSK9 catalytic activity.
An inhibition assay comprising:
- one or more cells comprising a first expression vector capable of expressing a catalytic protein fragment,
- a second expression vector capable of expressing a prodomain fragment and
- an indicator cleavably linked to the prodomain fragment, wherein the catalytic fragment cleaves the indicator from the prodomain fragment to provide a detectable indicator that can be used to screen molecules for inhibition of the activity of the catalytic protein fragment.
An inhibition assay comprising:
- a catalytic protein fragment disposed within a cell, and
- a prodomain fragment comprising an indicator disposed within the cell, wherein the catalytic fragment cleaves the indicator from the prodomain fragment to indicate catalytic activity.
A method of determining PCSK9 activity inhibition comprising the steps of:
- providing an inhibition assay comprising one or more HEK-293 cells comprising a catalytic fragment expression vector capable of expressing amino acids 153-692 of a catalytic fragment of PCSK9, a prodomain expression vector capable of expressing amino acids 31-152 of a prodomain of PCSK9 and a GFP labeled V5 protein capable of forming a V5-prodomain of PCSK9 fusion protein, wherein the catalytic fragment of PCSK9 cleavage of the GFP from the V5-prodomain of PCSK9 fusion protein to releases the GFP as a detectable label
- contacting the inhibition assay with a sample suspected of comprising a PCSK9 activity inhibitor;
- and
- detecting the presence of the GFP label to determine the inhibition of the PCSK9 activity inhibitor.
A PCSK9 activity inhibition assay system comprising:
- one or more HEK-293 cells comprising
- a catalytic fragment expression vector capable of expressing amino acids 153-692 of a catalytic fragment of PCSK9;
- a prodomain expression vector capable of expressing amino acids 31-152 of a prodomain of PCSK9;
- and
- a GFP labeled V5 protein capable of forming a V5-prodomain of PCSK9 fusion protein, wherein the catalytic fragment of PCSK9 cleavage of the GFP from the V5-prodomain of PCSK9 fusion protein to releases the GFP as a detectable label.
Dependencies are inferred from the claim text.